AzTrials
AzTrials

StenosesETNANCT07727824

Endoscopic Treatment

A study testing Informed consent, Eligibility criteria check and Randomisation in people with Stenoses and Dyspnea, run by University Hospital, Toulouse at 6 sites in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The placement of an endoprosthesis in the airways leads to rapid and dramatic clinical improvement in the majority of cases of central airway obstruction. However, the limited diversity of device shapes available on the market is a major limitation, as these devices are poorly adapted, or not adapted at all, to the… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Stenoses, Dyspnea
What is being tested?
Informed consent, Eligibility criteria check and Randomisation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
96 participants
Where
6 sitesFrance
Study dates
Jan 2027to Jan 2031
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age >18 years,
  • Central non-malignant symptomatic (dyspnea > grade 2 mMRC or post-stenotic infection) airway stenosis with silicone stent implantation indication (viable downstream airways, pulmonary artery and parenchyma),
  • To have access to a personal telephone for the teleconsultation scheduled in the protocol,
  • Informed consent signed,
  • Health insurance beneficiary.

Who cannot join

  • Acute respiratory distress,
  • Mechanical ventilation,
  • Contraindication to rigid bronchoscopy: severe coagulation disorders that cannot be corrected, anticoagulant or antiplatelet therapy other than aspirin within 5 days prior to the stent implantation,
  • Malignant stenosis,
  • Pregnancy or breast-feeding,
  • A situation in which emergency or semi-emergency intervention (less than 48 hours) may be anticipated (like an acute respiratory distress for example),
  • Patient under legal protection, - Participation in another study with an exclusion period still in progress,
  • Impossibility of giving the person informed information and of ensuring the subject's compliance due to impaired physical and/or psychological health.

Trial locations and contacts

6 sites in 1 country. Contact the study team or a site near you to ask about taking part.

6 sites in 1 country

France6 sites
  • Hôpital Marie Lannelongue / Institut Gustave Roussy

    Le Plessis-Robinson, 92350

    Amir HANNA, Dr, 6 46 92 57 71 ext. +33, a.hanna@ghpsj.fr

    Adrian CRUTU, Dr, 1 40 94 25 78 ext. +33, a.crutu@ghpsj.fr

  • Institut Cœur Poumon - CHU Lille

    Lille, 59037

    Clément FOURNIER, Dr, 3 20 44 44 34 ext. +33, clement.fournier@chu-lille.fr

    Frédéric WALLYN, Dr, 7 86 18 82 45 ext. +33, frederic.wallyn@chu-lille.fr

  • CHU Limoges

    Limoges, 87000

    Thomas EGENOD, Dr, 5 55 05 68 92 60 ext. +33, thomas.egenod@chu-limoges.fr

  • CHRU Strasbourg

    Strasbourg, 67000

    Michele PORZIO, Dr, 3 69 55 13 74 ext. +33, michele.porzio@chru-strasbourg.fr

    Cezar Aurelian MATAU, Dr, 3 69 55 07 27 ext. +33, cezaraurelian.matau@chru-strasbourg.fr

  • Hôpital Foch

    Suresnes, 92150

    Daniela USTUROI, Dr, 6 45 91 66 63 ext. +33, medic.pneumo@yahoo.com

  • Larrey Hospital

    Toulouse, 31059

    Nicolas GUIBERT, Pr, +33 (0)5 67 77 81 60, guibert.n@chu-toulouse.fr

Other trials in France

About this study

Official title: Endoscopic Treatment With 3D Customized Versus Standard Stent for Non-malignant Airway Stenoses: A Randomized Controlled Trial

The placement of an endoprosthesis in the airways leads to rapid and dramatic clinical improvement in the majority of cases of central airway obstruction. However, the limited diversity of device shapes available on the market is a major limitation, as these devices are poorly adapted, or not adapted at all, to the patient's anatomy. The main consequences of this lack of congruity are stent migration and granulomatous inflammatory reactions. The investigators hypothesized that personalized endoprostheses could significantly reduce the complication rate and improve tolerability. In this randomized controlled trial, the investigators propose to evaluate whether personalized endoprostheses allow for better management of non-malignant central airway stenoses by comparing this new approach to standard care.

Conditions
Stenoses, Dyspnea
Being tested
Informed consent, Eligibility criteria check, Randomisation, Dyspnea-12 questionnaire, VQ11 questionnaire
Keywords
Non-malignant Airway stenoses, Endoscopic Treatment, 3D customized stent, stent
Medical subject headings
Constriction, Pathologic, Dyspnea

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Informed consentOther

    During the pre-inclusion/inclusion visit, the investigator informs the participant and answers all questions regarding the purpose, nature of the constraints, foreseeable risks and the expected benefits of the clinical investigation. The investigating physician then provides the participant with a copy of the information note and informed consent form. After this information session, the participant is granted a reflection period. If the participant agrees to participate

  • Eligibility criteria checkOther

    The investigator also specifies the participant's rights in the context of research and checks the eligibility criteria.

  • RandomisationOther

    When an investigator wishes to perform the randomisation after checking the eligibility criteria and consent of the participant, he/she will connect to the dedicated Clinsight Website.

  • Dyspnea-12 questionnaireBehavioural

    The DYSPNEA-12 questionnaire helps to understand how shortness of breath impacts a patient's life. This questionnaire contains 12 questions that assess the physical and emotional aspects of dyspnea in daily life by checking one of the following boxes: not at all, slightly, moderately, severely

  • VQ11 questionnaireBehavioural

    The VQ11 questionnaire is a quality of life questionnaire. It contains 11 statements that express feelings about the consequences of a respiratory illness. For each statement, the patient must check the intensity that corresponds to their experience from among: not at all, a little, moderately, a lot, and extremely.

  • EQ-5D-5L questionnaireBehavioural

    This questionnaire assesses the patient's mobility, autonomy, activities, pain, and anxiety using 5 items. For each item, the patient must select the situation that best describes them from among 5 options: no problem, mild problems, moderate problems, severe problems, or unable to function.

  • SpirometryOther

    non-invasive measurement of ventilatory function, including peak expiratory flow and forced expiratory volume in 1 second (FEV1)

  • Chest CT scanRadiation

    High resolution chest CT scan without injection of contrast medium. The scanner required for the manufacture of the prosthesis must be a high-resolution CT scanner, the recommendations for which are specified in the order file for a 3D stent

  • Commercially Stent ImplantationProcedure or surgery

    During the commercially stent implantation, a video of the procedure will be recorded and all the pseudonymized videos of each center will be centralized and stored in the pulmonology department of Pr Nicolas Guibert of CHU of Toulouse.

  • Experimental Stent ImplantationProcedure or surgery

    During the experimental stent implantation, a video of the procedure will be recorded and all the pseudonymized videos of each center will be centralized and stored in the pulmonology department of Pr Nicolas Guibert of CHU of Toulouse.

Study groups in NCT07727824
Study groupRoleWhat they receive
Experimental groupExperimentalAfter computer-assisted segmentation of the airways and correction of the stenosis VGStudioMAX 3.0) using the CT data, a virtual stent (AnatomikModeling) and mold are designed. The latter is then 3D printed and used for the stent fabrication in silicone (NOVATECH) which is inserted through a rigid bronchoscope.
Receives: Other: Informed consent; Other: Eligibility criteria check; Other: Randomisation; Behavioral: Dyspnea-12 questionnaire; Behavioral: VQ11 questionnaire; Behavioral: EQ-5D-5L questionnaire; Other: Spirometry; Radiation: Chest CT scan; Procedure: Experimental Stent Implantation
Control groupActive comparatorCommercially available stents (NOVATECH) are inserted following the exact same modalities (general anesthesia) and tools (rigid bronchoscope, rigid forceps) than for 3D stents.
Receives: Other: Informed consent; Other: Eligibility criteria check; Other: Randomisation; Behavioral: Dyspnea-12 questionnaire; Behavioral: VQ11 questionnaire; Behavioral: EQ-5D-5L questionnaire; Other: Spirometry; Radiation: Chest CT scan; Procedure: Commercially Stent Implantation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of patients (Cox model) experiencing one or more severe stent and/or procedure-related complication(s)

    Rate of patients (Cox model) experiencing one or more severe stent and/or procedure-related complication(s)

    Measured: 47 months

Secondary outcomes (9)
  1. Rate (percent) of all adverse events

    Rate (percent) of all adverse events at 3, 6 and 12 months, specifying the causal relationship with the procedure and the MD (certain, probable, possible, not-related) and the intensity (grade).

    Measured: 15 months

  2. Evolution in dyspnea

    Evolution in dyspnea by mMRC from baseline to 3, 6 and 12 months of follow-up using a Student's t-test.

    The mMRC (MODIFIED MEDICAL RESEARCH COUNCIL) is a scale for assessing dyspnea. There are five stages of dyspnea, numbered from 0 to 4, with 4 being the stage where shortness of breath is most severe.

    Measured: 15 months

  3. Evolution in dyspnea

    Evolution in dyspnea by dyspnea 12 from baseline to 3, 6 and 12 months of follow-up using a Student's t-test The DYSPNEA-12 questionnaire helps to understand how shortness of breath impacts a patient's life. This questionnaire contains 12 questions that assess the physical and emotional aspects of dyspnea in daily life by checking one of the following boxes: not at all, slightly, moderately, severely

    Measured: 15 months

  4. Evolution of quality of life

    Evolution of quality of life by VQ11 questionnaire from baseline to 3, 6 and 12 months of follow-up using a Student's t-test. The VQ11 questionnaire is a quality of life questionnaire. It contains 11 statements that express feelings about the consequences of a respiratory illness. For each statement, the patient must check the intensity that corresponds to their experience from among: not at all, a little, moderately, a lot, and extremely.

    Measured: 15 months

  5. Evolution of quality of life

    Evolution of quality of life by EQ-5D-L questionnaire from baseline to 3, 6 and 12 months of follow-up using a Student's t-test.

    The EQ-5D-5Lquestionnaire assesses the patient's mobility, autonomy, activities, pain, and anxiety using 5 items. For each item, the patient must select the situation that best describes them from among 5 options: no problem, mild problems, moderate problems, severe problems, or unable to function.

    Measured: 15 months

  6. Change in pulmonary function tests

    Change in pulmonary function tests by pulmonary function tests from baseline to 3 and 12 months using a Student's t-test

    Measured: 15 months

  7. Change in pulmonary function tests

    Change in pulmonary function tests by FEV1 from baseline to 3 and 12 months using a Student's t-test.

    FEV1 is a non-invasive measurement of ventilatory function, including peak expiratory flow and forced expiratory volume in 1 second

    Measured: 15 months

  8. Change in pulmonary function tests

    Change in pulmonary function tests by Forced Vital Capacity from baseline to 3 and 12 months using a Student's t-test

    Measured: 15 months

  9. Change in pulmonary function tests

    Change in pulmonary function tests by the peak flow from baseline to 3 and 12 months using a Student's t-test

    Measured: 15 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jul 2026
  2. Study startJan 2027 (estimated)
  3. Primary completionJan 2031 (estimated)
  4. Study completionJan 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
96 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07727824
Sponsor's protocol ID
RC31/24/0324
Acronym
ETNA
Status last verified
Jul 2026
First submitted
24 Jun 2026
Last updated
27 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Informed consent, Eligibility criteria check and Randomisation in people with Stenoses and Dyspnea, run by University Hospital, Toulouse at 6 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Audrey TOMASIK (+33 (0) 5 61 77 85 97, tomasik.a@chu-toulouse.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of patients (Cox model) experiencing one or more severe stent and/or procedure-related complication(s) (time frame: 47 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in